NUWELLIS INC
NUWENASDAQTrading Snapshot
- Day Range
- $3.36 โ $3.41
- 52-Week Range
- $2.52 โ $1,556.10
- Volume (shares)
- 8,988
- Avg Volume (shares)
- โ
- Shares Outstanding
- 540,000
- Next Earnings
- 2027-03-08
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $2M
- P/E Ratio
- โ
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-1,382.26
- Dividend Yield
- โ
- Dilution (1yr)
- โ52.1%
NUWELLIS INC
NUWEAbout NUWELLIS INC
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
Live discussion will feature study investigators examining clinical findings, treatment outcomes, and the role of ultrafiltration in pediatric fluid management Live discussion will feature study investigators examining c

Nuwellis, Inc. (NUWE) Q3 2026 Earnings Call Transcript
Nuwellis, Inc. (NUWE) Q3 2026 Earnings Call Transcript

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
Console unit sales increased 88% year-to-date versus prior-year period, expanding its installed base to drive future recurring circuit revenue Advanced growth strategy with 510(k) submission for Aquadex label expansion a

Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flowยฎ Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
MINNEAPOLIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has secured e

Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlowยฎ Indication to Include Pediatric Patients Weighing 5 kg and Above
Submission represents a significant regulatory milestone in advancing access to precision fluid management for smaller pediatric patients Submission represents a significant regulatory milestone in advancing access to pr

Nuwellis to Report Third Quarter 2026 Financial Results on November 12
MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report financial re